

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Gladwin *et al.*

**Application No.** 10/563,683

**Filed:** October 4, 2006

**Confirmation No.** 3225

**For:** USE OF NITRITE SALTS FOR THE TREATMENT  
OF CARDIOVASCULAR CONDITIONS

**FILED VIA EFS**

**Examiner:** Anna Pagonakis

**Art Unit:** 1628

**Attorney Reference No.** 4239-67618-07

SUBMITTED VIA ELECTRONIC FILING SYSTEM  
UNITED STATES PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT PURSUANT TO**  
**37 C.F.R. § 1.97(c)**

Listed on the accompanying form PTO-1449 and submitted herewith are three English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement (IDS) is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Submitted electronically herewith is the fee of \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c). Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Jodi L. Connolly/  
Jodi L. Connolly, Ph.D.  
Registration No. 54,044

cc: Docketing  
Accounting